Here are 68 books that The Great American Drug Deal fans have personally recommended if you like
The Great American Drug Deal.
Book DNA is a community of 12,000+ authors and super readers sharing their favorite books with the world.
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
This account of the early years of Vertex Pharmaceuticals, from its inception as a scrappy start-up to its early work in HIV, is a must-read classic for anyone interested in how science turns into new drugs. Barry Werth’s journalistic play-by-play is a cinematic, true-to-life picture of the strategic decisions, real-world challenges, and larger-than-life personalities that underlie modern drug development. His riveting follow-up, The Antidote, continues the saga by taking readers through Vertex’s pathbreaking work to transform the care of patients with hepatitis C and cystic fibrosis.
It is April 1st, 2038. Day 60 of China's blockade of the rebel island of Taiwan.
The US government has agreed to provide Taiwan with a weapons system so advanced that it can disrupt the balance of power in the region. But what pilot would be crazy enough to run…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
Since Nixon’s "War on Cancer," oncology treatment has seen some great advances, but also the approval of scores of over-priced drugs that do little to improve patients’ quality or quantity of life. Oncologist Vinay Prasad has written a broad, accessible overview of the flaws of modern cancer drug development that spans clinical trial design, conflicts of interest, regulatory policy, and more. His unabashedly anti-pharma stance gets preachy in places, but most of the challenges he identifies are spot-on and provide a thought-provoking roadmap for the future.
How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective.
Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel-but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology…
Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
A key issue about drug pricing not covered in Kolchinsky's book relates to value: even if a new therapy is affordable, is it "worth it"? Health economist Peter Neumann and his colleagues have written an authoritative, insightful, and extremely accessible history of efforts to align drugs' prices with their benefits to patients and society. This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade.
The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only…
A Duke with rigid opinions, a Lady whose beliefs conflict with his, a long disputed parcel of land, a conniving neighbour, a desperate collaboration, a failure of trust, a love found despite it all.
Alexander Cavendish, Duke of Ravensworth, returned from war to find that his father and brother had…
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
The COVID-19 pandemic has been burned into the memory of the world. While millions died as a result of this virus, many more would have died if not for the discovery, development, and deployment of the mRNA vaccines. Pfizer CEO Albert Bourla takes you behind the scenes of the race to find this breakthrough vaccine, detailing the risks undertaken, the challenges that were faced, and the crises that were ultimately overcome to save the world.
I found this riveting account inspiring from both a scientific and leadership perspective.
The exclusive, first-hand, behind-the-scenes story of how Pfizer raced to create the first Covid-19 vaccine, told by Pfizer's CEO Dr. Albert Bourla
A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made "the impossible possible"-creating, testing, and manufacturing a safe and effective Covid-19 vaccine that previously would have taken years to develop.
Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer, under the enormous strains of the global pandemic, overcame a…
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
How do you put a price on life? That is a question often asked as healthcare providers seek to determine what is a fair price for a new life-saving drug. European governments have come up with a methodology called QALY (“Quality Adjusted Life Year”), which assigns a monetary value to the quality of life and survival length for patients and then assesses the cost-effectiveness of a drug based upon the drug’s potential to both improve a patient’s quality of life and extend that life.
That sounds pretty reasonable. Actually, it isn’t. This book shows that adopting the QALY methodology in the US would be harmful by limiting patient access to breakthrough medicines as well as discouraging investment into the biotech sector by not rewarding innovation.
While policymakers have often expressed sticker shock at the prices of certain therapies to treat life-threatening illnesses and are right to explore options to lower costs of treatment, one methodology they should reject is the Quality Adjusted Life Year (QALY) standard used in the U.K. and elsewhere. QALY assigns a monetary value to the quality of life and survival-length for patients. QALY has generated controversy, including in the U.K., where its use led to delays in the approval of new cancer treatments already widely available in other countries—and meant the deaths of patients waiting for those potentially lifesaving treatments. In…
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
There are a lot of critics of the biopharmaceutical industry who belittle the contributions of this industry by accusing it of overselling the value of new medicines, underselling safety, and having numerous conflicts of interest with academic researchers.
This book details the importance of collaborations between doctors and industry for the development of new drugs. For anyone involved in pharmaceutical R&D, it is refreshing to read accounts about successful interactions that lead to breakthroughs.
Rather than look at healthcare as “good guys vs. bad guys,” this book gives great examples of partnerships that result in saving lives.
The Duke's Christmas Redemption
by
Arietta Richmond,
A Duke who has rejected love, a Lady who dreams of a love match, an arranged marriage, a house full of secrets, a most unneighborly neighbor, a plot to destroy reputations, an unexpected love that redeems it all.
Lady Charlotte Wyndham, given in an arranged marriage to a man she…
I am the former president of Pfizer Global Research, where I led research groups around the globe in finding new medicines to treat cancer, addiction, AIDS, immunological diseases, and pain. After retiring from Pfizer, I have been closely involved with biotech companies that also are seeking breakthrough drugs. This industry is a crucial part of the healthcare ecosystem, as evidenced by the remarkable response and, ultimately, the crushing of the COVID-19 pandemic. Yet, it is not just underappreciated but is treated with scorn by many. This booklist provides sources from which the reader can gain a full understanding of the value of the biopharmaceutical industry, the challenges it faces, and its importance to the world’s health.
The biopharmaceutical industry needs great young scientists. I often get asked by science majors as to whether they should consider a job in this industry and how to be successful in it. For these folks, I recommend Creating Cures, which is a thoughtful and thorough description of a career that combines doing great science with an eye on the business of developing great new medicines.
Reading this book could help you land the job of a lifetime.
Born and raised in the Chicago area, I worked in the automotive industry as a car salesperson and racing team manager, financial services as a Registered Representative, and a member of the Chicago Board Options Exchange. An expat in Panama since 2004, I worked in business development for several healthcare products and co-founded an air medical transport service. Over the last decade, I’ve represented two businesses delivering protective medical care to high-net-worth individuals where I learned care’s gold standard from former White House physicians. My research included the books I recommend here and inspired me to write the Expat Health Guide for current and future expats.
Dr. Makary begins with an almost unreal story of a French citizen who had the unfortunate luck of having a heart attack in the US. I won’t give it away, but used car dealers come out smelling like roses, and I did that for a while, back in my youth. Such a lesson. Americans sorely need perspective on what great care is and how to pay for it. Dr. Makary does a fantastic job outlining two little-known middlemen sucking money out of American wallets. Pharmacy Benefit Managers, and Group Purchasing Organizations. Both use tactics that would make Tony Soprano smile.
What I love about this book, and why I recommend it, is while spotlighting problems, he offers solutions, and spotlights people making a difference.
"A must-read for every American and business leader." --Steve Forbes, editor-in-chief, FORBES
From the New York Times bestselling author of Unaccountable comes an eye-opening, urgent look at America's broken health care system--and the people who are saving it.
One in five Americans now has medical debt in collections and rising health care costs today threaten every small business in America. Dr. Makary, one of the nation's leading health care experts, travels across America and details why health care has become a bubble. Drawing from on-the-ground stories, his research, and his own experience, The Price We Pay paints a vivid picture…
Anna Malaika Tubbs is the author of the critically acclaimed book The Three Mothers: How the Mothers of MLK Jr., Malcolm X, and James Baldwin Shaped a Nation. She is also a Cambridge Ph.D. candidate in Sociology and a Bill and Melinda Gates Cambridge Scholar. After graduating Phi Beta Kappa from Stanford University with a BA in Anthropology, Anna received a Master’s from the University of Cambridge in Multidisciplinary Gender Studies. Outside of the academy, she is an educator and DEI consultant. She lives with her husband, Michael Tubbs, and their son Michael Malakai.
A crucial read not only for understanding the unique obstacles facing Black birthing parents but also for celebrating the work of organizers who have fought for our reproductive justice. This book explains how key moments in history have led to where we are today and fills gaps of understanding that many have when it comes to Black maternal health.
There is a global crisis in maternal health care for black women. In the United States, black women are over three times more likely to perish from pregnancy-related complications than white women; their babies are half as likely to survive the first year. Many black women experience policing, coercion, and disempowerment during pregnancy and childbirth and are disconnected from alternative birthing traditions. This book places black women's voices at the center of the debate on what should be done to fix the broken maternity system and foregrounds black women's agency in the emerging birth justice movement. Mixing scholarly, activist, and…
This book follows the journey of a writer in search of wisdom as he narrates encounters with 12 distinguished American men over 80, including Paul Volcker, the former head of the Federal Reserve, and Denton Cooley, the world’s most famous heart surgeon.
In these and other intimate conversations, the book…
As a cancer doctor, I have spent two decades dedicated to understanding the causes and therapy of cancer, how my patients experience their diagnosis and treatment, and how meaningful improvements in their experience should be reflected in the criteria we use to approve cancer drugs approval in the U.S., to improve their lives. In over 100 essays published in outlets like The New York Times and The Washington Post and in two books, I sing the stories of my patients as I learn from their undaunted spirits and their utter humanity, as I try to figure out how to be a better doctor, and a better person.
Nobody is perfect. But in medicine, not being perfect can cause injury in another person, or even death.
In When We Do Harm, Ofri tells the stories of patients who fell victim to medical errors, conducting root-cause analyses of how errors occur in the complicated practice of medicine, and the mundane interventions and cultural shift that will be necessary to prevent them in the future.
Medical mistakes are more pervasive than we think. How can we improve outcomes? An acclaimed MD’s rich stories and research explore patient safety.
Patients enter the medical system with faith that they will receive the best care possible, so when things go wrong, it’s a profound and painful breach. Medical science has made enormous strides in decreasing mortality and suffering, but there’s no doubt that treatment can also cause harm, a significant portion of which is preventable. In When We Do Harm, practicing physician and acclaimed author Danielle Ofri places the issues of medical error and patient safety front and…
